What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients by Rothermundt, C et al.
What is the role of routine follow-up
for localised limb soft tissue sarcomas?
A retrospective analysis of 174 patients
C Rothermundt*,1, J S Whelan2, P Dileo2, S J Strauss2, J Coleman3, T W Briggs3, S R Haile4 and B M Seddon2
1Division of Oncology/Haematology, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland; 2London Sarcoma Service, University
College London Hospitals, London NW1 2BU, UK; 3Department of Orthopaedic Surgery, Royal National Orthopaedic Hospital,
Middlesex HA7 4LP, UK and 4Clinical Trials Unit, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland
Background: There are neither prospective data nor agreement on the optimal routine follow-up procedures in patients treated
for soft tissue sarcoma of the limb.
Methods: Data on 174 consecutive patients with a soft tissue sarcoma of the limb undergoing follow-up by oncologists at a single
centre from 2003 to 2009 were included in this analysis. The rate and site of recurrence and mode of detection were analysed.
Outcome of the patients was assessed.
Results: Eighty-two patients (47%) experienced relapse of any type. Isolated local recurrence occurred in 26 patients and local
relapse with synchronous pulmonary metastases in five patients. Local recurrences were detected clinically in 30 of these 31
patients; magnetic resonance imaging identified only one local recurrence. Twenty-eight patients developed isolated lung
metastases; in nine patients these were amenable to resections, seven of whom are currently free of disease after treatment. Lung
metastases were detected by chest x-ray (CXR) in 19 patients, computed tomography scanning in 3 patients, and clinically in 11
patients. Twenty-three patients developed non-pulmonary metastases. More than 80% of relapses occurred in the first 2 years of
follow-up; however, later recurrences were also observed.
Conclusions: Routine follow-up CXR can detect lung metastases suitable for surgical resection, although the optimal interval of
imaging has yet to be defined. Local relapse is almost always detected by patients or physicians, and routine scanning of the
primary site is of doubtful benefit. Patient and physician education to detect local relapse may be helpful. Prospective evaluation
of follow-up is recommended.
Sarcomas are a rare and heterogeneous group of malignant
tumours of mesenchymal origin. They account foro1% of all new
cancer cases diagnosed in the UK each year. The number of new
cases diagnosed in England between 2000 and 2009 was 2626
(National Cancer Intelligence Network, 2012). Approximately 80%
of all sarcomas arise from soft tissue and the remaining from bone.
Soft tissue sarcomas (STS) most frequently originate within an
extremity (70%), followed by the trunk, retroperitoneum, and head
and neck (Zagars et al, 2003). The standard treatment of localised
STS of the extremities is limb-preserving surgery (Rosenberg et al,
1982; Potter et al, 1986), frequently in combination with adjuvant
or neoadjuvant radiotherapy in intermediate- and high-grade
disease (Barkley et al, 1988; Wilson et al, 1994; Wanebo et al, 1995;
Yang et al, 1998; O’Sullivan et al, 2002). This combined modality
treatment achieves 5-year local control rates of 80–90% and 5-year
disease-specific survival rates of 470% (Zagars et al, 2003). Local
recurrences have been documented to mostly occur up to 5 years
after completion of treatment (Ballo et al, 2004), and in synovial
sarcomas metastatic relapse has been shown to occur as late as 16.3
years after primary treatment (Krieg et al, 2011). A recent analysis
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of outcome in intermediate- and high-grade myxofibrosaromas
showed local recurrences in 31% of patients and distant
recurrences in 17%, indicating a more aggressive local behaviour
compared with other STS (Haglund et al, 2012).
Surveillance strategies in cancer are adopted for the following:
detection of local or distant recurrences based on the supposition
that early detection and treatment prolongs survival; detection of
secondary tumours or other relevant medical conditions, which
might have been caused by previous anti-cancer treatment; and as
a source of reassurance to the patient. However, there is concern
about the negative effects of using excessive radiation in
surveillance imaging of cancer survivors (Brenner and Hall, 2007;
Tarin et al, 2009) and about causing anxiety by frequent
investigations (Thompson et al, 2010).
There have been few prospective studies evaluating follow-up
strategies in common cancer types, and none in STS. In breast
cancer, survival has been shown to be equivalent with either
intensive or routine follow-up (Palli et al, 1999). In stage I non-
seminomatous germ cell tumours, the number of computed
tomography (CT) scans during post-treatment surveillance was
prospectively assessed and could be safely reduced from five to two
with equivalent patient outcomes (Rustin et al, 2007). Treating
patients with recurrent ovarian cancer on the basis of a rise in
CA125 levels alone did not achieve superior outcomes when
compared with deferring treatment to symptomatic relapse (Rustin
et al, 2010). In colorectal cancer there is evidence that follow-up
programmes for patients with curatively resected tumours improve
survival, although which tests or frequencies of visits are optimal
remains unclear (Figueredo et al, 2003). Recent data on
surveillance in diffuse large B-cell lymphoma demonstrated that
scanning detected diffuse large B-cell lymphoma relapse prior to
clinical manifestations in only 8 out of 537 patients (1.5%)
(Thompson et al, 2013).
Because of the lack of prospective data, follow-up recommenda-
tions for STS after primary curative treatment are based on expert
opinions and vary in frequency and modality. All include regular
chest imaging and some include routine imaging of the primary
site (Grimer et al, 2010; ESMO/European Sarcoma Network
Working Group, 2012; NCCN, 2014). A 2004 survey in UK cancer
centres illustrates wide variations in follow-up practices, with little
consistency on imaging, follow-up intervals, or duration of follow-
up (Gerrand et al, 2007). An ideal surveillance schedule should
meet the criteria of easy implementation, efficiency in detection of
recurrence, and cost effectiveness.
The aim of this study was to describe the presentation of relapse,
the modality of detection of recurrence, and patient outcomes, and
to assess the effectiveness of current unit follow-up guidelines. We
retrospectively assessed all patients who presented with STS of the
limb between December 2003 and December 2009 at a large
regional specialist non-surgical sarcoma unit who had undergone
resection of the primary tumour. Most patients were referred for
evaluation for radiotherapy and chemotherapy, thus representing a
high-risk group of patients.
PATIENTS AND METHODS
This retrospective analysis includes data on 174 patients with
localised STS of the limbs who presented as new patients at the
London Sarcoma Service at University College London Hospital
(UCLH) between December 2003 and December 2009. Patient and
tumour data were collected from hospital records.
Follow-up guidelines (Table 1) were implemented within the
London Sarcoma Service in April 2007; previously, post-treatment
surveillance was not standardised and was performed at the
discretion of the treating physician. However, follow-up practice
did not change substantially in the period prior to guideline
implementation.
The median follow-up duration of all patients was 32 (range 1–91)
months. For patients still alive median follow-up was 37 (range 1–91)
months, and for those who had died it was 18 (range 7–70) months.
Information retrieved included age at surgery, tumour site,
histological subtype, histological tumour grade (Coindre et al, 1988),
treatment modalities, date of recurrence, location of recurrence
(local, local and lung, lung only, non-pulmonary), mode of detection
of relapse, and treatment for recurrence. Time to relapse was
calculated from the date of completion of treatment to the date of
relapse, with the exception of patients who relapsed following
surgery and prior to starting adjuvant radiotherapy, when date of
surgery to the date of relapse was used. The method of Kaplan and
Meier was used for relapse-free survival analysis (Kaplan, 1958).
Statistical calculations were performed with R version 3.0.1 (CORE
TEAM R, 2013) and confidence intervals (CI) for median survival
were calculated (Brookmeyer and Crawley, 1982).
Data collection was in accordance with local ethical standards.
RESULTS
In total, 174 patients were assessed. Patient and tumour
characteristics are summarised in Table 2.
Of the 174 patients, 172 underwent surgery; two patients
received definitive combination chemo-radiation and underwent
no surgery. The mean age at surgery was 51 (range 13–88) years.
Radiotherapy was delivered to 145 of the 174 patients (83%) in
addition to surgery: 25 patients received preoperative radiotherapy,
and 118 patients received postoperative radiotherapy; two patients
received pre- and postoperative radiotherapy. Twenty-five (14%)
patients received neo- or adjuvant chemotherapy.
At the time of last follow-up, 116 patients (67%) were alive, 43
patients (25%) had died, and 15 (9%) were lost to follow-up (as
defined by no follow-up information within the last 12 months). At
the time of last follow-up, 112 patients (64%) were disease free.
Site of relapse. Tumour recurrence was experienced by 82
patients (47%). Sites of relapse are summarised in Table 3. Among
patients who received radiotherapy (147 patients), the overall
relapse rate was 42%, with a local relapse rate of 14%. In patients
treated with surgery alone (27 patients), the overall relapse rate was
78%, with a local relapse rate of 37%.
Time of relapse. The median relapse-free survival for the entire
group was 43.9 months (95% CI, 29.9 – infinity) (Figure 1).
Disease-free survival at 2 years was 61% (95% CI 53–68) and that
at 5 years was 42% (95% CI 32–51). Local relapse-free survival at
2 years was 75% (95% CI 67–81) and that at 5 years was 51% (95%
CI 39–62). Median time from end of treatment to relapse was
9 (range 0–49) months for local recurrence, 3 (range 0.6–15)
months for local relapse and synchronous lung metastases,
5 (range 1–66) months for lung metastases only, and 11 (range
3–52) months for non-pulmonary metastases (Figure 2). In some
of these patients local as well as systemic relapse occurred prior to
initiation of adjuvant radiotherapy.
During the first year 48 (59%) of 82 patients relapsed (13 local,
4 local with synchronous lung metastases, 18 lung relapses only),
and a further 18 patients relapsed during the second year of follow-
up (6 local, 1 local with synchronous lung metastases, and 5 lung
recurrences). There was one relapse beyond 5 years; however,
median follow-up was only 32 months.
Detection of relapse
Local relapse. Thirty of 31 local recurrences (97%) were detected
clinically. In 22 patients detection was by self-examination, and
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in 8 cases recurrence was noted on physical examination by the
physician at routine follow-up. Only one patient had an
asymptomatic local relapse detected on magnetic resonance
imaging (MRI), when repeat imaging was performed to reassess
a postoperative seroma.
Our current practice is to routinely perform an MRI of the
primary tumour site 6 months after completion of adjuvant
radiotherapy, to act as a post-treatment baseline for future
comparison. However, some patients underwent additional scans
routinely for local surveillance. In 16 patients with a local relapse
who had had a previous MRI not suspicious for recurrence, the
median time from MRI to clinical detection of relapse was 6 (range
3–19) months. This indicates that, despite recent normal imaging,
local recurrences were still detected clinically in this group of
patients. The median time from previous normal follow-up to local
relapse was 3 (range 1–28) months, which highlights the fact that
local relapses were noted between regular 3-monthly appointments
by the patient in the majority of cases.
Lung metastases. Twenty-eight patients (16%) developed isolated
lung metastases. Asymptomatic lung metastases were discovered
on routine chest X-ray (CXR) in 19 patients and by CT scanning in
3 patients at a median of 8 (range 1–66) months after completion
of initial treatment. Of the three patients who had CT scans, one
had indeterminate lung nodules on an original staging CT scan at
first diagnosis, and a repeat CT scan after 3 months confirmed
progression of the nodules, thereby diagnosing lung metastases;
two patients underwent CT scans for other reasons (to exclude an
axillary nodal recurrence; to reassess pelvic lymph nodes that had
been irradiated as part of primary treatment), and the lung
metastases were an incidental finding. As such, none of these three
patients represent a deviation from our defined follow-up guide-
lines. Symptomatic lung metastases occurred in 6 patients at 2, 3, 5,
5, 5, and 40 months after the end of primary sarcoma treatment
(median 5 months). The short time from initial treatment to
symptomatic relapse in five of these patients suggests aggressive
tumour biology. Relapse was detected at a median of 2 (range 1–5)
months after the last routine follow-up and normal imaging. The
patient with disease recurrence more than 3 years after surgery
developed symptoms of a pleural effusion secondary to lung
metastases, o3 months after a routine follow-up appointment.
Non-pulmonary metastases. Eighteen of 23 non-pulmonary
recurrences (lymph node, soft tissue, subcutaneous, bone, or
multiple sites) were discovered by the patients, one chest wall
recurrence was detected on physical examination, and one pelvic
and one mediastinal recurrence was noted on MRI and CT scans,
respectively. In two of the patients, routine CXR was suggestive of
lung metastases and further staging revealed additional non-
pulmonary metastases. Median time from last routine follow-up to
relapse with non-pulmonary metastases was 3 (range 1–9) months
(Figure 3).
Table 1. London Sarcoma Service follow-up guidelines
Grade Year 1 Year 2 Year 3–4 Year 5–10
Exam Clinical CXR MRI of the primary site Clinical CXR Clinical CXR Clinical CXR
Interval (months) Low 6 6 12 12
Interval (months) Intermediate/high 3 3 at 6 months 3 3 6 6 12 12
Abbreviations: CXR¼ chest X-ray; MRI¼magnetic resonance imaging.
Table 2. Patient and tumour characteristics
Characteristics total, n¼174
Age (range) 51 (13–88)
Gender 94 male 80 female
Grading n %
Low grade 1 1
Intermediate grade 15 9
High grade 156 90
No grade 2 1
Histologic subtype n %
Myxofibrosarcoma 37 21
Liposarcoma 34 20
Synovial sarcoma 29 17
Leimyosarcoma 10 6
Others 64 37
Localisation n %
Upper extremity 40 23
Lower extremity 134 77
Resection status n %
R0 158 91
R1 13 7
R2 1 1
No surgery 2 1
Table 3. Site of relapse
Relapse total, n¼82 (47%)
Site n %
Lung 28 16
Local and lung 5 3
Local 26 15
Non-pulmonary 23 13
Bone 6 3
Abdominal 4 2
Chest wall 2 1
Mediastinum 2 1
Pelvis 2 1
Soft tissue 2 1
Diffuse 2 1
Epigastrium 1 1
Groin 1 1
Subcutaneous 1 1
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Outcomes of relapsed patients
Local relapse. Fifteen of the 26 patients (58%) who experienced an
isolated local recurrence are alive, and 12 of those patients (46%)
are disease free with a median follow-up time of 22 (range 4–57)
months after the last recurrence. Nine patients are deceased, and
two are lost to follow-up.
In 20 of 26 patients, curative treatment for local tumour
recurrence was undertaken: surgery alone in 10 patients, surgery
and radiotherapy in 8 patients, surgery and chemotherapy in a
patient with synovial sarcoma, and chemotherapy alone in a
patient with extraosseus Ewing sarcoma. Eight patients did not
have a further relapse. However, 12 patients had another
recurrence: five were local (four of which were successfully
salvaged — 2 with further local resections and two with subsequent
limb amputation), four developed lung metastases, two developed
local relapse with synchronous lung metastases, and one patient
relapsed with non-pulmonary metastases (Figure 4).
Lung metastases. Nine of the 22 (41%) patients with imaging-
detected asymptomatic lung metastases (seven on CXR, two on CT
scan) underwent pulmonary metastatectomy with curative intent.
Eight of these patients are alive and seven are currently disease free
with a median follow-up time of 14 (range 6–38) months. In these
seven patients, the interval between primary sarcoma treatment
and detection of lung metastases was more than 6 months. Patients
had one to four metastases on preoperative scanning, and a
maximum of four metastases were removed at surgery. One patient
developed lung metastases shortly after initial primary treatment.
Whereas on the preoperative CT scan only 3 metastases were
visible, at surgery more than 20 metastases were resected. This
patient subsequently relapsed rapidly and died. Two patients were
treated with radiofrequency ablation for recurrent lung metastases;
one remains disease-free, while the other patient has relapsed
again.
Thirteen patients with CXR- or CT-scan-detected lung
metastases were considered unsuitable for pulmonary metastatectomy
owing to the extent of disease, and were treated with palliative
intent. Twelve patients have died since, and one patient was lost
to follow-up and has presumably died. Median time from relapse
to death was 13 (range 4–39) months.
The six patients with symptomatic lung relapse all had advanced
disease without curative treatment options. Five patients died of
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Figure 3. Patients with non-pulmonary metastases: Time from
treatment, last follow-up, and last CXR to relapse. Time (months).
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Figure 4. Treatment of local relapse and outcome.
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Figure 2. Relapse-free survival by site. Time (months).
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metastatic sarcoma and one was lost to follow-up. The short
interval from end of treatment to relapse indicates aggressive
disease with rapid progression.
In summary, 41% of patients with lung metastases detected on
routine imaging were treated with curative intent and 32% remain
free of disease at present. Of note, the seven patients who
underwent curative metastectomy and are disease free had a longer
relapse-free interval from primary treatment of 30 (range 9–66)
months compared with patients who had a subsequent relapse or
were not deemed suitable for surgical intervention with a median
relapse-free interval of 3 (range 1–22) months.
Non-pulmonary metastases. Thirteen of the 23 patients with non-
pulmonary metastases have died from metastatic sarcoma. Median
time from relapse to death was 8 (range 1–33) months. Two
patients were lost to follow-up and nine patients are still alive, two
of whom are currently disease free. Both of them had soft tissue
metastases amenable to resection at relapse.
DISCUSSION
The aim of this study was to assess the mode and effectiveness of
detection of relapse in patients undergoing surveillance for
extremity STS, and to identify optimal follow-up schedules. We
retrospectively analysed data from 174 patients who were treated at
a single centre over a period of 6 years. In our patient group with
mostly high-grade and therefore high-risk STS, the rate of local
relapse of 18% is consistent with other data sets in extremity STS
(Lawrence et al, 1987; Lewis et al, 1997; Eilber et al, 2003), as is the
rate of metastatic spread of 32% (Pisters et al, 1996; Huth and
Eilber, 1988; Billingsley et al, 1999b). The aim of any surveillance
programme is to identify relapses at such a time that the relapses
can be successfully treated, achieving long-term survival. In our
series, of the 31 patients with local recurrence, 46% are disease free
at a median follow-up of 22 months after recurrence, and of the 28
patients with lung metastases 32% who underwent metastasectomy
are disease free at a median follow-up of 14 months.
Of the 31 patients in our series with a local relapse, 97% of
relapses were detected clinically, 22 by the patients themselves and 8
by physicians in clinic. Only one local recurrence was asymptomatic
and detected on an MRI scan. This is consistent with a study that
evaluated the role of routine surveillance MRI scanning in the
detection of local recurrence for limb STS (Labarre et al, 2009). One
hundred and twenty-four patients underwent 663 planned MRI
scans according to a defined follow-up protocol. Of 11 local
recurrences (9%), nine were detected clinically and only two were
asymptomatic MRI-detected recurrences. This low screen detection
rate came at a cost of 11 false-positive MRI scans. Overall, the
authors concluded that clinical examination was a more effective
method of surveillance compared with routine MRI scanning.
A proportion of patients with STS who develop isolated relapse
in the lungs can be potentially cured by resection of lung
metastases (Billingsley et al, 1999a). In a series of 719 STS patients
with lung metastases, the median interval between the treatment of
the primary tumour and the development of metastatic disease was
10 months. Relapse-free interval was a prognostic indicator, with
an interval of 1 year or less being associated with poorer prognosis.
In another series, the number of nodules detected by CT scanning
preoperatively was found to have significant prognostic value, with
poorer outcomes for patients with four or more nodules (Casson
et al, 1992). Our patients with lung metastases who underwent
subsequent resection and are disease free had a median relapse-free
interval from primary treatment of 30 months, and had up to four
nodules removed. Patients in our series with symptomatic lung
metastases had a median time to relapse of 5 months, and none of
these patients were suitable for surgery. It seems unlikely that more
frequent surveillance would have altered outcomes in this patient
group, which probably reflects aggressive tumour biology.
The challenge of early detection of local relapse and metastatic
spread with a view to curative salvage treatment while preventing
unnecessary and even harmful investigations is yet to be solved.
Follow-up recommendations differ substantially in modality and
intensity and routine practice is even more diverse (Sakata et al,
2003; Gerrand et al, 2007). In a small retrospective analysis of
children diagnosed with relapsed soft tissue and bone sarcomas,
regular imaging studies (chest CT, MRI, and PET) did not lead to
earlier recognition of relapse and did not influence overall survival
(Postovsky et al, 2008).
Previously, Whooley et al published data on the efficacy of their
surveillance strategy in 174 patients with primary extremity STS
and provided a cost-effectiveness analysis (Whooley et al, 1999,
2000). Importantly, only 49% of sarcomas were high grade
compared with 90% in our series. They concluded differently in
their two publications: whereas they advocated physical examina-
tion, clinical assessment of patient symptoms, and CXR imaging as
effective strategies for follow-up of primary extremity STS in the
first publication (Whooley et al, 1999), they subsequently
postulated that more aggressive observation during the first 2
years after treatment with a 3-monthly physical examination and
CXR and cross-sectional imaging every 6 months where indicated
for 2 years would be appropriate in high-risk tumours with high
grade, large size, and deep localisation in the second publication
(Whooley et al, 2000). However, the accompanying editorial
(Brennan, 2000) raised several appropriate still unanswered
questions: ‘Is routine physician-directed follow-up justified if
50% of relapses are detected between regular visits? Is any imaging
of the primary tumour required if 86% of local relapses were
resectable and 19 of 20 were noticed on physical examination?
Furthermore, taking into account the negative impact on outcome
for a short interval from initial sarcoma treatment to pulmonary
relapse, this could be an argument against frequent scanning
during the first year of follow-up.’
The benefit and cost-effectiveness of chest CT as compared with
CXR for staging at initial sarcoma diagnosis was evaluated in two
studies (Fleming et al, 2001; Porter et al, 2002). However, these
results cannot be extrapolated to the follow-up situation and do not
inform on the best imaging modality. Recently a retrospective
analysis of 176 patients who were followed up with CT scans or
plain CXR for pulmonary metastasis monitoring after surgery for
STS was reported (Cho et al, 2011). As expected, there was a trend
towards unilaterality of lung metastases, smaller size, and manage-
ment with metastasectomy in the CT cohort. The 2- and 4-year
survival rates after detection of pulmonary metastasis were 20% and
0% in the plain radiograph cohort and 47% and 32% in the chest CT
cohort, respectively. These results should be interpreted with caution
because of the small number of patients in each cohort (26 and 28,
respectively). In our series of patients with lung relapses that were
mostly detected on CXR, outcomes appear broadly comparable to
other reports (Billingsley et al, 1999a), although our patient numbers
are small and follow-up is short for some patients.
There has been only one randomised trial of follow-up strategies
in sarcoma patients (Puri et al, 2014). This compared modality of
chest imaging (CXR and CT scans) and frequency of follow-up
(3-monthly and 6-monthly visits) in 500 patients with extremity
sarcomas (359 bone and 151 soft tissue sarcomas) in a two-by-two
factorial design. The results demonstrated non-inferiority of CXR
as compared with CT scans (3-year OS 67% and 66%, respectively;
DFS 54% and 49%, respectively). Three year OS was similar for
3-monthy and 6-monthly visits (69% and 64%, respectively); yet
the trial could not conclusively demonstrate non-inferiority for less
frequent follow-up visits. Interestingly, almost 90% of local
recurrences were found by patients themselves, which is very
consistent with our findings.
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ESMO guidelines for sarcoma acknowledge the lack of
published data on the optimal routine follow-up of patients with
localised disease treated by surgery (ESMO/European Sarcoma
Network Working Group, 2012). Imaging of the lungs is
advocated, in addition to clinical assessment of the primary site.
Follow-up intervals of 3–4 months in the first 2–3 years, 6-monthly
up to the 5th year, and annually thereafter are suggested.
Overall, regular CXR seems to be a feasible method of chest
surveillance considering the positive and negative predictive values of
surveillance CXR in STS of 92% and 97%, respectively (Whooley
et al, 2000). In a review on surveillance strategies for patients
following surgical resection of STS, the additional benefit of CT scans
of the lung was considered low, and the importance of thorough
history and physical examination was emphasised (Kane, 2004).
There are several limitations to our analysis: it was performed
retrospectively and follow-up was not performed according to
defined guidelines before April 2007. However, on comparing
patients who underwent treatment during the years 2003–2006 and
2007–2009, the recurrence-free survival curves appeared similar
and no significant changes in the relapse pattern could be observed
(P¼ 0.76, log-rank test). We only included STS of the limb in this
study and therefore no conclusions for surveillance strategies in
STS of other locations can be drawn, especially for retroperitoneal
sarcomas, where clinical assessment is difficult. Another limitation
of our study is in the heterogeneity of STS and the diverse
biological behaviour of the 450 histological subtypes, which
makes generalisations difficult. Furthermore, we are unable to
present an optimal schedule for the follow-up of soft tissue
sarcomas of the limb. However, we can conclude that regular
physical examination of the primary tumour site detects the vast
majority of local relapses. Moreover, in the light of our results and
the recent prospective randomised trial comparing radiological
modalities in the follow-up of extremity sarcomas (Puri et al,
2014), it appears that CXR may well be sufficient to detect lung
metastases amenable to resection, and that regular CT scans of the
lungs are unlikely to yield better results.
CONCLUSION
Patients with recurrent STS of the limb can potentially be salvaged
either by resection of local recurrence or by resection of distant
(usually lung) metastases. Surveillance should be directed at
detection of local relapse or lung metastases. Patient education
and awareness to detect local relapse should be encouraged. As a
minimum, regular CXR to detect lung metastases amenable to
resection should be performed, although the optimal interval of
imaging is not known, and it seems that patients developing lung
metastases during the first year after primary treatment have
particularly poor outcomes. The definition of a rational evidence-
based follow-up programme based on the risk of recurrence
remains to be established and needs prospective evaluation in
clinical trials.
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